Taking cell therapy to the next level with 3D bioprinting of human tissues

June 6, 2022

By combining cells, biomaterials, microfluidic engineering, and computational science, Aspect Biosystems is working to create breakthrough tissue therapeutics that have the potential to profoundly impact patients with 3D bioprinting of human tissues, contends Eric Roos, chief business development officer.

Roos told ScienceBoard.net at the American Society of Gene & Cell Therapy (ASGCT) 2022 annual meeting in Washington, DC, that the technology needed to take cell therapy to the next level with 3D bioprinting of human tissues is very complex.

Through the microfluidic 3D bioprinting of human tissues, Aspect is working to advance internal tissue therapeutic programs for regenerative medicine, with an initial focus on metabolic diseases such as type 1 diabetes and liver disease.

"The technology is really not about building an organ that would replace an organ," Roos said. "For example, a person that has type 1 diabetes has lost the function to maintain glucose at appropriate levels and can't control that metabolic function. They don't necessarily need a new pancreas, but they need to replace that lost function."

Roos said the goal in the case of a patient with diabetes is to "create that tissue that will provide that function, but not necessarily be a printed pancreas." Aspect is also forging external R&D partnerships with biopharmaceutical innovators in tissue engineering in fields such as orthopedics, neuroscience, and ophthalmology.

Watch the video below to learn more.


Overcoming the blood-brain barrier for gene therapy delivery with AAV capsids
Current gene delivery to the central nervous system continues to be a challenge, according to Amy Pooler, PhD, vice president of neuroscience at Sangamo...
Decibel Therapeutics develops treatments to restore and improve hearing, balance
Decibel Therapeutics is helping to break down the barriers to understanding the molecular pathways and cell physiology inside the inner ear by integrating...
Mustang Bio focuses on CD20 antigen for CAR T-cell therapy
Biopharmaceutical company Mustang Bio is focused on a CD20-targeted autologous chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma,...
Lexeo to start phase I/II clinical trial for patients with FA cardiomyopathy
Gene therapy company Lexeo Therapeutics in 2022 plans to launch a phase I/II clinical trial of its adeno-associated virus-based therapy designed to intravenously...
Graphite Bio sees its gene editing tech as step above CRISPR
While the use of CRISPR is an effective gene editing tool on its own, Dr. Josh Lehrer, CEO of Graphite Bio, contends that the technology doesn’t correct...
COVID-19 mRNA-based vaccines benefit from decades of research
25 years ago Dr. Drew Weissman, PhD, an infectious disease expert at Penn Medicine, and RNA biologist Kati Kariko, PhD, began their collaboration in...
Genenta Science reports preliminary results of Temferon-glioblastoma study
Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy, Temferon, for the treatment of a variety of solid tumor...
Next-generation AAV capsids hold key to developing life-changing therapies
Voyager Therapeutics’ discovery platform is identifying novel capsids targeting desired cells and tissues with greater specificity, at lower doses, and...
How to address challenges in producing AAV vectors
There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors,...
Atsena Therapeutics’ gene therapy takes aim at childhood blindness
In an interview with ScienceBoard.net, Patrick Ritschel, CEO of Ophthalmology-based gene therapy company Atsena Therapeutics, shared an overview...
Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation,...
Delivery of gene therapies remains a key challenge
Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge,...
Next evolution of CAR T-cell therapy is solid tumors
While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the...

Copyright © 2022 scienceboard.net

Last Updated 6/6/2022 10:02:53 AM